Over-the-counter progesterone creams are another example. These are "natural" because they are produced from wild yams and plants, but they lack the process that makes them "bio-identical"; therefore, little progesterone is absorbed from the product. 3 Medroxyprogesterone is entirely synthetic. It is a progestin and quite unlike the chemical structure of human progesterone. The goal of BHRT is to restore a balance between hormone levels, utilizing compounds that mimic endogenous hormones.
■ The Progression of HRT
In the 1930's, natural hormones were available,but when given orally,they were rapidly destroyed in the gastrointestinal tract. Technology was not available to protect the substance from rapid degradation. More effective means of replacing the hormones (other than painful oil-based injections) were necessary.
Equine estrogens were developed in the 1940's and researched over several decades with better absorbency results. 4 These had widespread success in managing menopausal symptoms, were well-researched, and heavily marketed over a period of time.
Initially, unopposed estrogen increased the risk of uterine cancer in women who had not undergone a hysterectomy, and in the 1970's, progestin was added, 5 setting the stage for current therapy. But despite traditional therapy's reported success, more women began looking for an alternative.
In the 1980's, a process was discovered that slowed the 
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Illustration by David Newton release of bio-identical hormones, allowing effective absorption and increases in serum levels of hormone. 1 Because these products are 1)found in nature, 2) lacking a unique extraction process, and 3) dosed so that therapy is completely individualized, an approval from the FDA has not been sought commercially. 6 ■ Why Advocate HRT? Traditional therapy includes the use of daily conjugated equine estrogen combined with medroxyprogesterone for a woman with an intact uterus. Studies have indicated relief of the vasomotor and genitourinary symptoms resulting from menopause, as well as the prevention of osteoporosis.
Hot flashes, sweats, genitourinary atrophy, sexual dysfunction, skin changes, and the psychological and somatic symptoms of menopause are distressing and disrupting to a woman's lifestyle, and are often the main reasons women seek HRT. HRT generally is quite effective in relieving the majority of these complaints. 7 Osteoporosis benefits were substantiated in the Postmenopausal Estrogen and Progestin Interventions (PEPI) Trial, which demonstrated increases in bone density among hormone therapy users. 8 Recent meta-analyses of several studies over the past 3 decades demonstrated that HRT made significant improvements in bone mineral density, but data was inconclusive on whether actual reduction in vertebral fracture rates occurred. Nonvertebral fractures were significantly reduced. 9, 10 The cardiovascular benefits of HRT came to light as a secondary gain of estrogen therapy, despite the increased risk of thromboembolic events. However, the American Heart Association (AHA) recently changed its position on the use of HRT in women with cardiovascular disease, as evidence mounts against the use of estrogen/progestin therapy in regard to heart and vascular health.
The Heart and Estrogen/Progestin Replacement Study (HERS) trial did not meet expectations that heart disease is reduced with HRT. HRT mortality did not decrease, and women were more at risk during the first year of therapy for cardiovascular events. Lipid levels were also not favorably decreased with HRT. In general, the AHA's stance is that HRT should not be started for the sole purpose of cardiovascular protection, but individually prescribed for its other documented benefits. 11 Moreover, the Women's Health Initiative halted their study of combined estrogen and progestin use in postmenopausal women after a little more than 5 years. The safety board concluded that the risk of cardiovascular disease and breast cancer, although small, was significant enough to outweigh the benefits. 28 The link to these increased risks appears to be progestin. The estrogen arm of the study continues.
■ The Setting for HRT The major sex hormones are estrogen, progesterone, and androgens, primarily testosterone and dehydroepiandrosterone (DHEA). The estrogen portion is actually composed of three estrogens: estrone (E 1 ), estradiol (E 2 ), and estriol (E 3 ). These exist in a balance of about 10% estrone, 10% to 20% estradiol, and 70% to 80% estriol. Estrone is the most potent and estriol has the weakest activity. These three estrogens are highest in activity during the first half of the menstrual cycle.
Estradiol is primarily produced by the ovary, whereas estrone is converted from androstenedione in body tissue,and estriol is converted from precursors in the liver. 12 Once the ovaries fail, overall estrogen levels fall. Then estrone becomes the primary estrogen, and estradiol is deficient. Estrone is abundantly converted in subcutaneous fat, and heavier women may have an overall higher estrogen level than thinner women because of this. 12 Ten to 20% of women may have enough endogenous estrogen after menopause to build the endometrial lining just through conversion via the fat cells. 4 The last half of the menstrual cycle, known as the luteal phase, is dominated by progesterone. Progesterone begins to decrease after age 35 when the ovaries begin to deteriorate, causing a luteal phase deficiency and potentially resulting in irregular or heavy periods, spotting, and increased symptoms of premenstrual syndrome. Levels of progesterone fall substantially after menopause. 4 Testosterone levels decline gradually with age, generally to less than half of premenopausal levels. Oophorectomized women may see a more dramatic decrease. 13 Patients who are extremely stressed, both physically and psychologically, may note a decrease in DHEA. In addition,there is an age-related decline in DHEA levels marked in the fifth and sixth decades. 13 There is also a suggestion that 
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the decrease in androgens may be related to diseases associated with aging, but not necessarily menopause. 29 Deficiencies can be detected by serum or saliva levels of hormones. 1 Serum levels are most available to practitioners, while saliva levels are obtained through a variety of commercial labs. Saliva testing is popular with those who specialize in BHRT because it is easy to use and inexpensive to obtain. There is evidence that saliva accurately correlates with serum levels. Steroid hormones readily diffuse into saliva and are an accurate reflection of free hormone levels (those hormone molecules that are not protein-bound).
14 Saliva samples are stable for a prolonged period of time. Several mail-order companies will do hormone testing without a health care provider's order and include an explanation of the lab tests in correlation with a patient's symptoms. Providers and patients should make sure that the labs are federally certified (CLIA or COLA), which guarantees they are reliable and routinely inspected.
There is no standard practice protocol for measuring hormone levels. Current practice does not routinely check progesterone or estradiol levels in the treatment of perimenopausal or postmenopausal women. Often, follicle stimulating hormone (FSH) is checked to determine if a woman is in menopause. 30 However, other hormone levels can be reliably tested and utilized to map a treatment plan. 2, 16 The goal of BHRT is to regain the balance of the hormones in the body. Without knowing what imbalance exists, the plan is hard to produce (see Tables: "Hormone Levels and Possible Corresponding Symptoms"and "Checking Hormone Levels"). The results of these laboratory tests, accompanied by clinical symptoms, can guide the practitioner in prescribing the bio-identical hormone regimen that is best for the patient. Therapy should be reviewed and revised as symptoms warrant.
■ BHRT Vs. Conventional HRT:
A common question regarding BHRT is what makes this a reasonable alternative to conventional therapy? The answer is complex. After all, traditional HRT has a great deal of research in support of its benefits with regard to symptom relief and bone health. Yet, only 10-25% of menopausal women are taking hormones,only half of the prescriptions written for HRT are filled, and only 40% of women who begin therapy are still on it after a year. 3 Fear of breast cancer, lack of knowledge regarding HRT, and troublesome side effects are common reasons why therapy is never started or is discontinued prematurely. 3 Side effects such as weight gain, uterine bleeding, breast ten- derness, and bloating are most common, and usually associated with the progestin component of the drugs. 4 BHRT reportedly gives similar protection against bone loss and endometrial cancer as conventional therapy, with increased compliance and satisfaction. One retrospective study of 100 patients in a particular practice revealed a 96% compliance rate with BHRT and statistically significant improvement for 24 of 37 symptoms of hormonal imbalance. This far outweighs the compliance rate with traditional therapy. 1 A reason for this could be that these women may be more involved in their health care than average patients.
However, supporters of BHRT often quote the beneficial results of traditional therapy studies, and claim the conventional products are unsafe or lacking in full efficacy. 3 In view of side effects and low long-term compliance, the supporters are correct, but raw data in sufficient quantities has yet to support BHRT's claims of efficacy and safety.
BHRT does not have double blind, random, placebo controlled trials to back up its claims. However, there are several studies with small sample sizes that do show encouraging conclusions. For example, a study by Hargrove et al detailed a comparison of BHRT with synthetic replacement. The results were promising in regard to symptom relief, spotting, and hormone levels, but the sample size was less than fifty. 17 A Japanese study in 1996 featured 75 women with decreased bone density tests using estriol for nearly a year with prevention of further bone loss and improved climateric symptoms. 18 Estriol is very popular in Europe for HRT, and several large, controlled studies have shown decreased urinary tract infections in postmenopausal women as well as improved lipid panels and menopausal symptoms. 19, 20, 21 These studies are somewhat old, however, and have not been reproduced in current practice.
Oral micronized progesterone compared to medroxyprogesterone did receive a favorable report in the PEPI trial, a large and well-controlled study. 1 Additionally, a recent study of 58 women revealed that the topical application of progesterone did have an anti-proliferative effect on the endometrium without significant side effects. 22 Vasomotor symptoms treated with topical progesterone were improved in a controlled study of 100 women, though no improvement in bone density was noted with progesterone alone. 23 DHEA was shown to be effective in a 12-month study, with positive outcomes on bones, menopausal symptoms, and the endometrium. Although the p values were significant, there were no controls or randomization. 24 Anecdotally, there appears to be a positive correlation to DHEA-S levels and longevity, but there are few studies to prove a safe use for supplementation. It is sometimes used for treatment of depression, dysthymia, lupus, and adrenal insufficiency, and has shown promising results. Independent validation of risk/benefit ratio has yet to be determined. 13 In a study, 75 oophorectomized women were evaluated for testosterone replacement for a period of three months. Researchers concluded that transdermal testosterone improved sexual function and psychological well-being. This study had a placebo group and subjects were randomly assigned. 25 Testosterone levels did rise in serum as well. Estrogen therapy itself, as well as oopherectomy and menopause, can drive testosterone levels down. This gives an opportunity to rebalance with supplementation. 26 Although the theories are logical and preliminary results promising, a large, well-controlled study should be designed, 
Checking Hormone Levels
• Hormone levels should be checked in the midluteal phase in premenopausal or perimenopausal women for best results.
• Remember this is a tool in the total assessment picture to validate symptoms and diagnosis.
• Utilize the reference ranges given by the laboratory. If a particular lab is at an extreme in the normal range, but symptoms fit, treatment with follow up is appropriate.
• An estrone level could be warranted in heavier women who may have a lot of stored estrogen.
• Look at the balance of progesterone and estrogen-is the estrogen high normal, where the progesterone is low normal or low? If symptoms also fit, you could use a progesterone compound to treat estrogen dominance.
• If women are already on hormone replacement of any type, draw labs 8 hours post dosing for accuracy.
submitted, funded and completed to verify the claims made by those who support compounded BHRT. However, the observations of those who prescribe these regimens and individualize treatment for both premenopausal and postmenopausal women, give practitioners an alternative when conventional therapy has not worked or is initially unacceptable to the patient.
■ Replacement Options
Traditional hormone replacement includes products such as Premarin, Premphase, and Prempro, which are conjugated equine estrogen products. The progesterone component that is most frequently prescribed is medroxyprogesterone, such as Provera, which is not actually progesterone, but a progestin. Progestin versus progesterone creates a significant difference in side effects, and is often the reason why conventional therapy is prematurely discontinued. 4 Commercially prepared bio-identical hormones are available. Estradiol, one of the estrogen triad, is available in both oral forms, such as Activella, and patches including Climara, Vivelle, and other products. These are often covered under prescription plans.Prometrium is a bio-identical progesterone in a peanut oil (beware of allergies) that is commercially available, though frequent dosing is necessary.
Alternatively, compounded BHRT has endless combinations that can be individually determined and prescribed. A compounding pharmacist trained in BHRT is an invaluable asset when beginning this type of treatment 2 (see Table: "Examples of BHRT Dosing"). Remember, there are no trade names for these products and they are only available at compounding pharmacies.Reliable compounding pharmacies can be found by checking with Professional Compounding Centers of America (PCCA) or the International Academy of Compounding Pharmacists (IACP). Comparing symptoms and serum levels, one can determine what hormones should be balanced. Usually, it is advisable to start conservatively and have the patient reevaluated regularly to adjust dosages for symptoms relief. It is important to remember that these drugs are just like the commercially-prepared products, and have similar side effects (see Table: "Side Effects of BHRT"). Women who are not eligible for traditional HRT, and those with a history of breast cancer or thromboembolic events should not use BHRT.
Of course, besides pharmaceutical treatment options, the primary care provider should provide education and support. HRT, whether traditional or bio-identical, is not a magic bullet. Recommendations should include stress relief, proper nutrition and sleep, weight reduction, and smoking cessation. Testosterone cream 10mg/ml, 1-2mg per day (this is available as an oral sustained release, but better results are obtained when given topically without harmful liver effects). are often overlooked when completing an assessment and treatment plan of the premenopausal, perimenopausal, and postmenopausal woman. 27 
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■ Conclusion
Each woman should be evaluated individually to meet her particular needs and become fully informed of her options. BHRT is not the answer for every woman, just as traditional therapy does not fit every patient.
BHRT's are at a disadvantage because they lack long-term, controlled studies, making acceptance difficult to earn. Patients should be aware of this before starting this regimen. Observationally, there are a number of success stories, and research continues to provide an evidencebased approach to this treatment. The PEPI trial was a giant step in affirming the benefits of oral micronized progesterone therapy.
Hopefully, in time, more results will become available regarding other BHRT options. Currently, guidelines state that HRT should be used as a short-term relief for menopausal symptoms, with a full understanding of the risks and benefits. 30 Acquiring a knowledge base regarding all types of therapy will benefit both providers and patients.
